文献速递免疫规划传染病防控与疫情报告

卡介苗接种后疫苗不良事件的特征与发病率:2013至2017年日本全国监测研究

Characteristics and incidence of vaccine adverse events after Bacille Calmette-Guérin vaccination: A national surveillance study in Japan from 2013 to 2017.
PubMed 文献 · Vaccine · 2022-06-08

日本2013年将卡介苗推荐接种年龄改为5-8月龄(最新修订为<1岁)。本研究收集2013年4月至2017年3月<1岁人群卡介苗不良事件数据,分析发病率并比较<6月龄与≥6月龄接种者。共记录581例不良事件,<6月龄接种者卡介苗相关骨炎/骨髓炎发病率高于≥6月龄接种者,提示2013年推荐年龄调整可能促成后续骨炎/骨髓炎发病率下降。

要点

  • 共记录581例卡介苗相关不良事件,平均接种年龄5.7月龄,男性354例(61%)。
  • 每百万<1岁人口发病率最高为化脓性淋巴结炎(63.7),其次皮肤病变(38.4),骨炎/骨髓炎(3.1)。
  • <6月龄接种者骨炎/骨髓炎发病率(3.8)和播散性卡介苗(1.3)高于≥6月龄接种者。

核心结论

  • <6月龄接种卡介苗人群较≥6月龄接种人群更易发生卡介苗相关骨炎/骨髓炎,提示2013年推荐接种年龄调整可能促成后续骨炎/骨髓炎发病率下降。

研究设计与样本

  • 全国监测研究,收集2013年4月至2017年3月<1岁人群卡介苗相关疫苗不良事件数据。
  • 利用政府网站的人口普查和疫苗覆盖率数据计算发病率,并比较<6月龄与≥6月龄接种者的不良事件发病率。

主要发现

  • 研究期间共记录581例卡介苗相关不良事件,其中男性354例(61%),平均接种年龄5.7月龄。
  • 每百万<1岁人口接种时发病率:化脓性淋巴结炎63.7,皮肤病变38.4,卡介苗相关骨炎/骨髓炎3.1。
  • 播散性卡介苗和过敏反应罕见,分别占1.1%和1.6%。
  • <6月龄接种人群卡介苗相关骨炎/骨髓炎发病率(3.8)和播散性卡介苗发病率(1.3)高于≥6月龄接种人群。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Japan amended the recommended age for the Bacille Calmette-Guérin (BCG) vaccination to less than 6 months after 2005, but subsequently amended the recommended age to 5-8 months (latest amendment, <1 year) in April 2013 due to the increasing incidence of BCG-associated osteitis/osteomyelitis since 2005. METHODS: We collected data on BCG-associated vaccine adverse events (VAEs) in the population aged <1 year between April 2013 and March 2017. The incidence of BCG-associated VAE was analyzed using census and vaccine coverage data from the government website. We compared the incidence of VAEs in patients vaccinated at less than 6 months with those vaccinated at 6 months or older. RESULTS: Among the 581 BCG-associated VAEs recorded during the study period, 354 (61%) were male, and the average age at vaccination was 5.7 months. The incidence of VAEs per million population aged <1 year at vaccination was highest for suppurative lymphadenitis (63.7), followed by skin lesions (38.4), and BCG-associated osteitis/osteomyelitis (3.1). Disseminated BCG and anaphylaxis were rare (1.1 and 1.6%, respectively). The incidence of VAEs in the population vaccinated at <6 months of age was higher for BCG-associated osteitis/osteomyelitis (3.8) and disseminated BCG (1.3) than in the population vaccinated at ≥6 months. CONCLUSIONS: The population vaccinated at <6 months of age was more likely to develop BCG-associated osteitis/osteomyelitis than the population vaccinated at ≥6 months of age, indicating that the change in the recommended vaccination age in 2013 might have contributed to the subsequent decrease in the incidence of BCG-associated osteitis/osteomyelitis.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Okuno H, Satoh H, Morino S, et al. Characteristics and incidence of vaccine adverse events after Bacille Calmette-Guérin vaccination: A national surveillance study in Japan from 2013 to 2017. Vaccine. 2022. PMID: 35690499. doi:10.1016/j.vaccine.2022.05.055

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。